Amit Agrawal

Dr. Agrawal drives pharma industry’s largest clinical development portfolio. He joined Novartis in 2018 from Amgen where he was Head of Corporate Strategy. At Amgen, he was responsible for managing strategic planning processes and communications to the Board, company-wide resource allocation planning and transformation, and driving M&A (e.g., Amgen’s acquisition of Onyx) and capital investment projects. Prior to Amgen, he was at McKinsey and finished a postdoc from MIT, where he developed and tested siRNA delivery formulations in ovarian cancer and Glioblastoma mouse models. He finished his graduate studies in Biomedical Engineering/nanotechnology from Georgia Tech, where he developed reagents, assays, and instruments for ultrasensitive biological detection/ imaging at Georgia Tech. He has an undergraduate and master’s degree in Chemistry from the Indian Institute of Technology, Kanpur. He has also worked at two startups, one of which was a small, public biotech company where he served as chief operating officer. He is an author on over 20 research articles, and in his spare time, he plays percussions for charitable causes.